Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026)
Contineum Therapeutics (CTNM) posted quarterly Income from Continuing Operations of 56780000.0 for Q2 2026, down 149.44% year-over-year from 114846555.89 in Q2 2025, and down 36.94% quarter-over-quarter from 41463000.0 in Q1 2026.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 56780000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 149.44% year-over-year to 56780000.0; the TTM figure through Jun 2026 stood at 147034000.0 (down 129.78% YoY), while the FY2025 annual figure was 107813000.0, down 223.05% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 56780000.0, down from 41463000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 41571000.0 in Q2 2023, with the low at 56780000.0 in Q2 2026.
- The 4-year median for Income from Continuing Operations is 11236000.0 (2023), against an average of 15011285.71.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 53.46% in 2024, then slumped 219.79% in 2025.
- Contineum Therapeutics' Income from Continuing Operations stood at 12205000.0 in 2023, then surged by 53.46% to 5680000.0 in 2024, then plunged by 180.95% to 15958000.0 in 2025, then tumbled by 255.81% to 56780000.0 in 2026.
- Business Quant data shows CTNM's Income from Continuing Operations at 56780000.0 in Q2 2026, 41463000.0 in Q1 2026, and 15958000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Contineum Therapeutics | 621.59 Mn | 621.59 Mn | - | -15.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.09 Mn |
| Mar 31, 2026 | -17.42 Mn |
| Dec 31, 2025 | -15.11 Mn |
| Sep 30, 2025 | -12.98 Mn |
| Jun 30, 2025 | -15.87 Mn |
| Mar 31, 2025 | -18.01 Mn |
| Dec 31, 2024 | -5.68 Mn |
| Sep 30, 2024 | -10.27 Mn |
| Jun 30, 2024 | -9.01 Mn |
| Mar 31, 2024 | -8.42 Mn |
| Dec 31, 2023 | -12.21 Mn |
| Sep 30, 2023 | -6.25 Mn |
| Jun 30, 2023 | 41.57 Mn |
| Mar 31, 2023 | -4.82 Mn |